-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on Tarsus Pharmaceuticals, Raises Price Target to $51

Benzinga·05/05/2025 15:07:38
Listen to the news
Goldman Sachs analyst Andrea Tan maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Neutral and raises the price target from $46 to $51.